Effects of pentoxifylline administration on urinary N-acetyl-β-glucosaminidase excretion in type 2 diabetic patients: A short-term, prospective, randomized study

American Journal of Kidney Diseases

Volumn 42, Issue 2, 2003, Pages 264-270

  Navarro, Juan F ^a   Mora, Carmen ^b   Muros, Mercedes ^b   Macía, Manuel ^b   García, Javier ^b  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^b NONE

Author keywords

Diabetes mellitus (DM); N acetyl glucosaminidase (NAG); Pentoxifylline (PTF); Proteinuria; Tubulointerstitial damage

Indexed keywords

N ACETYL BETA GLUCOSAMINIDASE; PENTOXIFYLLINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; EVALUATION; FEMALE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SEX RATIO; URINARY EXCRETION;

EID: 0043128884     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(03)00651-6     Document Type: Article

References (33)

1. Price RG: Measurement of N-acetyl-β-glucosaminidase and its isoenzymes in urine. Methods and clinical applications. Eur J Clin Chem Clin Biochem 30:693-705, 1992
2. Gunder WG, Hofmann W: Markers for the diagnosis and monitoring of renal tubular lesions. Clin Nephrol 38:S3-S7, 1992 (suppl 1)
3. Jung K, Pergande M, Schimke E, Ratzmann KP, Ilius A: Urinary enzymes and low-molecular-mass proteins as indicators of diabetic nephropathy. Clin Chem 34:544-547, 1988
4. Watts GF, Vlitos MA, Morris RW, Price RG: Urinary N-acetyl-beta-D-glucosaminidase excretion in insulin-dependent diabetes mellitus: Relation to microalbuminuria, retinopathy and glycemic control. Diabetes Metab 14:653-658, 1988
5. Lorini R, Scaramuza A, Cortona L, Valenti G, D'Annunzio G, D'Eril GVM: Increased urinary N-acetyl-β-glucosaminidase (NAG) excretion in young insulin-dependent diabetic patients. Diabetes Res Clin Pract 29:99-105, 1995
6. Ward A, Clissold SP: Pentoxifylline: A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34:50-97, 1987
7. Tripathy K, Prakash J, Appaiha D, Srivastava PK: Pentoxifylline in management of proteinuria in diabetic nephropathy. Nephron 64:641-642, 1993
8. Guerrero-Romero F, Rodríguez-Morán M, Paniagua-Sierra J, García-Bulnes G, Salas-Ramírez M, Amato D: Pentoxifylline reduces proteinuria in insulin-dependent and non-dependent diabetic patients. Clin Nephrol 43:116-121, 1995
9. Navarro JF, Mora C, Rivero A, et al: Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: Effects of pentoxifylline administration. Am J Kidney Dis 33:458-463, 1999
10. Shibasaki T, Nakano H, Ohno I, Ishimoto F, Sakai O: Effect of pentoxifylline on CdC12-induced nephrotoxicity in the rat. Biol Trace Elem Res 41:245-251, 1994
11. Kim YK, Yoo JH, Woo JS, Jung JS, Kim BS, Kim SY: Effect of pentoxifylline on ischemic acute renal failure in rabbits. Ren Fail 23:757-772, 2001
12. Wardle EN: Can pentoxifylline prevent renal disease? Ren Fail 20:437-440, 1998
13. Skrha J, Haas T, Sperl M, Stibor B, Stolba P: A six-year follow-up of the relationship between N-acetyl-beta-glucosaminidase and albuminuria in relation to retinopathy. Diabet Med 8:817-821, 1991
14. Mocan Z, Erem C, Yildirim M, Telatar M, Deger O: Urinary beta2-microglobulin and urinary N-acetyl-beta-D-glucosaminidase enzyme activities in early diagnosis of non-insulin-dependent diabetes mellitus nephropathy. Diabetes Res 26:101-107, 1994
15. Ikenaga H, Suzuki H, Ishii N, Itoh H, Saruta T: Enzymuria in non-insulin-dependent diabetic patients: Signs of tubular cell dysfunction. Clin Sci 84:469-475, 1993
16. Perez-Blanco FJ, Sabatel-Hernandez G, Cantero-Hinojosa J, Rodriguez-Cuartero A: Urinary N-acetyl-beta-glucosaminidase excretion in non-insulin-dependent diabetes mellitus: Relation with diabetic nephropathy. Clin Nephrol 49:132-134, 1998
17. Yamanouchi T, Kawasaki T, Yoshimura T, et al: Relationship between serum 1,5-anhidroglucitol and urinary excretion of N-acetylglucosaminidase and albumin determined at onset of NIDDM with 3-year follow-up. Diabetes Care 21:619-624, 1998
18. Fujita H, Narita T, Morii T, et al: Increased urinary excretion of N-acetylglucosaminidase in subjects with impaired glucose tolerance. Ren Fail 24:69-75, 2002
19. Perdichizzi G, Cucinotta D, Fera R, Di Cesare E, Campo S, Squadrito G: Correlation between urinary activity of N-acetyl-beta-D-glucosaminidase (NAG) and albumin excretion rate in type 11 (non-insulin-dependent) diabetic subjects. Acta Diabetol Lat 24:149-155, 1987
20. Ambrus JL, Anain JM, Anain SM, et al: Dose-response effects of pentoxifylline on erythrocyte filterability: Clinical and animal model studies. Clin Pharmacol Ther 48:50-57, 1990
21. Daly JW, Padgett W, Shamin MT, Butts-Lamb P, Waters JL: 1,5-Dialkyl-8-(p-sulphophenyl)xanthines: Potent water soluble antagonists for A1- and A2-adenosine receptors. J Med Chem 28:487-492, 1985
22. Gilbert RE, Cooper ME: The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury? Kidney Int 56:1627-1637, 1999
23. Chouinard S, Viau C: Reversibility of renal tubular dysfunction in streptozotocin-induced diabetes in the rat. Can J Physiol Pharmacol 70:977-982, 1992
24. Itoh Y, Nakai A, Kakizawa H, et al: Alteration of endothelin-1 concentration in STZ-induced diabetic rat nephropathy. Effects of PGI(2) derivate. Horm Res 56:165-171, 2001
25. Fede C, Conti G, Chimenez R, Ricca M: N-Acetyl-β-D-glucosaminidase and β2-microglobulin: Prognostic makers in idiopathic nephrotic syndrome. J Nephrol 12:51-55, 1999
26. Bazzi C, Petrini C, Rizza V, et al: Urinary N-acetyl-β-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant 17:1890-1896, 2002
27. Cooper ME, Jerums G, Gilbert RE: Diabetic vascular complications. Clin Exp Pharmacol Physiol 24:770-775, 1997
28. Cooper ME: Pathogenesis, prevention and treatment of diabetic nephropathy. Lancet 352:213-219, 1998
29. Petersen TC: Pentoxifylline prevents fibrosis in an animal model and inhibits platelet-derived growth factor-driven proliferation of fibroblasts. Hepatology 17:486-493, 1993
30. Windmeier C, Gressner AM: Effect of pentoxifylline on the fibrogenic functions of cultured rat liver fat storing cells and myofibroblasts. Biochem Pharmacol 51:577-584, 1989
31. Peterson TC: Inhibition of fibroproliferation by pentoxifylline. Activity of metabolite-1 and lack of role of adenosine receptors. Biochem Pharmacol 23:597-602, 1996
32. Han J, Thompson P, Beutler D: Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signalling pathway. J Exp Med 172:393-394, 1990
33. Doherty GM, Jensen JC, Alexander HR, Buresh CM, Norton JA: Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 110:192-198, 1991